London’s FDI Offers Help To Mid-Size Indian Drug Makers, Biotechs
This article was originally published in PharmAsia News
London's foreign direct investment agency is looking at medium-size drug makers as possible targets for assisting in expanding their plans in Europe. Think London already is in negotiations with five unidentified Indian firms, offering help with agreements between them and 100 London-based drug makers and biotechs. The union is designed to help the Indian firms get market access to local regulatory agencies in Europe. Past clients in India include Arch Pharma, Aurobindo Pharma and Intas Pharmaceutical. (Click here for more
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.